z-logo
Premium
Disruption of Me CP 2 attenuates circadian rhythm in CRISPR /Cas9‐based Rett syndrome model mouse
Author(s) -
Tsuchiya Yoshiki,
Minami Yoichi,
Umemura Yasuhiro,
Watanabe Hitomi,
Ono Daisuke,
Nakamura Wataru,
Takahashi Tomoyuki,
Honma Sato,
Kondoh Gen,
Matsuishi Toyojiro,
Yagita Kazuhiro
Publication year - 2015
Publication title -
genes to cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.912
H-Index - 115
eISSN - 1365-2443
pISSN - 1356-9597
DOI - 10.1111/gtc.12305
Subject(s) - biology , rett syndrome , crispr , circadian rhythm , rhythm , microbiology and biotechnology , neuroscience , biochemistry , medicine , gene
Methyl‐CpG‐binding protein 2 ( Mecp2 ) is an X‐linked gene encoding a methylated DNA ‐binding nuclear protein which regulates transcriptional activity. The mutation of MECP 2 in humans is associated with Rett syndrome ( RTT ), a neurodevelopmental disorder. Patients with RTT frequently show abnormal sleep patterns and sleep‐associated problems, in addition to autistic symptoms, raising the possibility of circadian clock dysfunction in RTT . In this study, we investigated circadian clock function in Mecp2 ‐deficient mice. We successfully generated both male and female Mecp2 ‐deficient mice on the wild‐type C57 BL /6 background and PER 2 Luciferase ( PER 2 Luc ) knock‐in background using the clustered regularly interspaced short palindromic repeats ( CRISPR )/Cas9 system. Generated Mecp2 ‐deficient mice recapitulated reduced activity in mouse models of RTT , and their activity rhythms were diminished in constant dark conditions. Furthermore, real‐time bioluminescence imaging showed that the amplitude of PER 2 Luc ‐driven circadian oscillation was significantly attenuated in Mecp2 ‐deficient SCN neurons. On the other hand, in vitro circadian rhythm development assay using Mecp2 ‐deficient mouse embryonic stem cells ( ESC s) did not show amplitude changes of PER 2 Luc bioluminescence rhythms. Together, these results show that Mecp2 deficiency abrogates the circadian pacemaking ability of the SCN , which may be a therapeutic target to treat the sleep problems of patients with RTT .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom